RFCA
CORT icon

R&F Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

R&F Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-37,270
Closed -$271K – 705
2016
Q4 		$271K Buy
+37,270
New +$292K 0.1% 333

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

R&F Capital Advisors's CORT Position: Q1 2017 in Review

R&F Capital Advisors sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 37,270 shares — an estimated $271K sold.

R&F Capital Advisors first reported a position in CORT in Q4 2016 and held it in 1 quarter. The position peaked at $271K in Q4 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

  • R&F Capital Advisors reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 37,270 Corcept Therapeutics shares in Q1 2017, an estimated $271K.
  • R&F Capital Advisors first reported a position in Corcept Therapeutics in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Corcept Therapeutics position peaked at $271K in Q4 2016.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.